FORT LAUDERDALE, Fla., Aug. 09, 2017 -- OmniComm Systems, Inc., (OTCQX:OMCM), a leading global provider of clinical data management technology, has a new technology partner in Japan. SRD Co., Ltd., a contract research organization (CRO) in Tokyo, has selected OmniComm’s TrialMaster electronic data capture (EDC) technology to support clinical trial research for pharmaceutical, medical devices and related healthcare products. The agreement represents the first contract for TrialMaster in Japan.
“SRD selected TrialMaster EDC because it offers efficient and easy support, and provides site users with easy-to-use data entry screens that support high-quality data capture and avoid unnecessary system-generated queries,” said Akira Sugihara, general manager of SRD’s data science department. “In addition, OmniComm provides excellent support – in the local language – for our study-build activities, operational challenges and our business development activities.”
TrialMaster was selected for its speed of study build, flexibility and multilingual capabilities, but most of all, for its unique ability to both transpose data and export data in SDTM format directly from the EDC solution. Compelling TrialMaster features include: intuitive user interface, real-time edit checks, real-time reporting and the ability to customize data exports. OmniComm’s technology transition deployment model, which allows customers to build their studies while OmniComm manages the hosting in its state-of-the-art data centers, was another critical factor in the selection process.
“We started preparing to bring TrialMaster to the Japanese market in 2016. In Japan, more so than any other country, it requires not only a superior product, but above all, endurance and focus to bring a new technology to the market and secure your first customers,” said Wolf Ondracek, senior vice president at OmniComm, with responsibility for the Asia-Pacific region. “The fact that SRD, a local Japanese CRO, has chosen TrialMaster as its EDC system for industry-sponsored trials is a tremendously important milestone. I am confident that it marks the start of the successful penetration of the Japanese market for our flagship EDC solution, TrialMaster.”
Specific emphasis for TrialMaster’s selection included:
- Ability to build studies more efficiently and effectively.
- Adeptness in query management work flow.
- Intuitive interface for all key user groups.
- Dynamic monitoring and centralized source review.
- Ability to export SDTM datasets directly from TrialMaster using Custom Export Utility Tool™.
- Broad range of pre-built, real-time standard reports and best-in-class, real-time ad-hoc reporting.
- Flexible and very user-friendly eLearning modules.
- Professional and experienced regional-based services and support organization.
Supporting Information
- OmniComm Systems Signs Fifth TrialOne Contract in China in Four Months
- OmniComm Systems® Announces the Go-Live of TrialOne® at Seoul National University Hospital
- OmniComm Systems Experiencing Rapid Adoption of TrialOne® in China
- OmniComm Systems Announces First Australia Client
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 5,000 clinical trials. For more information, please visit: omnicomm.com
About SRD Co., Ltd.
SRD is a Tokyo-based, mid-size Japanese CRO, established in 1989. The company offers a full range of CRO services, including monitoring, QA and GCP services, data management and biostatistics, drug management, medical writing, pharmacovigilance and regulatory consulting. For further details, please visit: http://www.cro-srd.co.jp/
Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info Kuno van der Post OmniComm Systems, Inc. +1.954.473.1254 [email protected]


Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
Instagram Outage Disrupts Thousands of U.S. Users
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 



